Originally published as JCO Early Release 10.1200/JCO.2004.04.105 on February 23 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langer, C. J. Articles by Johnson, D. H. Search for Related Content PubMed PubMed Citation Articles by Langer, C. J. Articles by Johnson, D. H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CARBOPLATIN PLATINUM COMPOUNDS TAXOL Medline Plus Health Information Lung Cancer Related Articles Related Editorial Related Correspondence Social Bookmarking                            What's this?

Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598

From the Fox Chase Cancer Center, Philadelphia, PA; Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA; Oklahoma University Health Science Center, Oklahoma City, OK; and Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN

Address reprint requests to Corey J. Langer, MD, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111; e-mail: CJ_Langer{at}fccc.edu

PURPOSE: Multiple non–small-cell lung cancer (NSCLC) cell lines and 20% to 50% of pathologic specimens express HER-2/neu, the target of trastuzumab, and HER-2/neu expression has proven to be an independent, unfavorable prognostic factor in resected patients with NSCLC. Trastuzumab, in vitro, has demonstrated growth-inhibiting synergy with platinating agents, and additivity with paclitaxel. The Eastern Cooperative Oncology Group therefore launched a phase II study evaluating combination carboplatin, paclitaxel, and trastuzumab in patients with advanced NSCLC.

MATERIALS AND METHODS: Eligibility stipulated the following: measurable tumor, HER-2/neu positivity (1+ to 3+ by Herceptest [Dako Corp, Carpinteria, CA], confirmed by central review), Eastern Cooperative Oncology Group PS 0 to 1, adequate marrow, hepatic and renal function, and left ventricular ejection fraction 45%. Patients received paclitaxel 225 mg/m²/3 hours, and carboplatin (area under the curve, 6) every 3 weeks, and trastuzumab 4 mg/kg intravenously on day 1, then 2 mg/kg weekly for 1 year.

RESULTS: Between August 1999 and May 2000, 139 patients were screened; seven specimens (5%) were indeterminate. Fifty patients (36%) were HER-2/neu negative, 38 (27%) were HER-2/neu 1+, 31 (22%) were 2+, and 13 (9%) were 3+. Fifty-six patients were enrolled; 53 were eligible (22 [42%] were 1+, 23 (43%) were 2+, and eight (15%) were 3+). Thirteen (24.5%) of 52 assessable patients (95% CI, 13.8 to 38.3) responded. The incidence of grade 3 neutropenia and thrombocytopenia was 57% (34%) and 16% (2%), respectively. Asymptomatic grade 2 reduction in left ventricular ejection fraction occurred in 7%. Other nonhematologic toxicities, including nausea, fatigue, arthralgias, and peripheral sensory neuropathy, were mild to moderate and matched those expected with carboplatin and paclitaxel alone. Eighteen patients (35%) received maintenance trastuzumab. Median progression-free survival was 3.3 months; median survival was 10.1 months, and 1-year survival rate was 42%.

CONCLUSION: Combination paclitaxel, carboplatin, and trastuzumab is feasible. Toxicity appears no worse than cytotoxic therapy alone. Overall survival is similar to historical data using carboplatin and paclitaxel alone. However, patients with 3+ HER-2/neu expression did well in contrast to historical data suggesting potential benefit for trastuzumab in this rare subset of NSCLC. Critical assessment of trastuzumab's role in advanced NSCLC will require phase III trials.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Toward Customized Trastuzumab in HER-2/neu-Overexpressing Non-Small-Cell Lung Cancers
  Rafael Rosell
  JCO 2004 22: 1171-1173 [Full Text]

Related Correspondence

• Targeted Therapy for Targeted Patients: Trastuzumab in Adjuvant Treatment of Non–Small-Cell Lung Cancer
  Kadri Altundag, Ozden Altundag, Paolo Morandi, and Mehmet Gunduz
  JCO 2005 23: 1325 [Full Text]
• Trastuzumab in the Treatment of Advanced Non–Small-Cell Lung Cancer: Is There a Role?
  Gregory Kalemkerian
  JCO 2005 23: 1325-1326 [Full Text]

This article has been cited by other articles:

				L. Horn and A. Sandler Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Clin. Cancer Res., August 15, 2009; 15(16): 5040 - 5048. [Abstract] [Full Text] [PDF]

				T. A. D'Amico Molecular Biologic Staging of Lung Cancer Ann. Thorac. Surg., February 1, 2008; 85(2): S737 - S742. [Abstract] [Full Text] [PDF]

				P. A. Janne, J. von Pawel, R. B. Cohen, L. Crino, C. A. Butts, S. S. Olson, I. A. Eiseman, A. A. Chiappori, B. Y. Yeap, P. F. Lenehan, et al. Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2007; 25(25): 3936 - 3944. [Abstract] [Full Text] [PDF]

				M. Mizukami, T. Hanagiri, M. Yasuda, K. Kuroda, Y. Shigematsu, T. Baba, T. Fukuyama, Y. Nagata, T. So, Y. Ichiki, et al. Antitumor Effect of Antibody against a SEREX-Defined Antigen (UOEH-LC-1) on Lung Cancer Xenotransplanted into Severe Combined Immunodeficiency Mice Cancer Res., September 1, 2007; 67(17): 8351 - 8357. [Abstract] [Full Text] [PDF]

				T. A. d'Amato, R. J. Landreneau, W. Ricketts, W. Huang, R. Parker, E. Mechetner, I.-R. Yu, and J. D. Luketich Chemotherapy resistance and oncogene expression in non-small cell lung cancer J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 352 - 363. [Abstract] [Full Text] [PDF]

				C. Swanton, A. Futreal, and T. Eisen Her2-targeted therapies in non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4377s - 4383s. [Abstract] [Full Text] [PDF]

				B. E. Johnson and P. A. Janne Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4436s - 4440s. [Abstract] [Full Text] [PDF]

				D. H. Johnson Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s. [Abstract] [Full Text] [PDF]

				T. A. d'Amato, R. J. Landreneau, R. J. McKenna, R. S. Santos, and R. J. Parker Prevalence of In Vitro Extreme Chemotherapy Resistance in Resected Nonsmall-Cell Lung Cancer Ann. Thorac. Surg., February 1, 2006; 81(2): 440 - 447. [Abstract] [Full Text] [PDF]

				F. Cappuzzo, M. Varella-Garcia, H. Shigematsu, I. Domenichini, S. Bartolini, G. L. Ceresoli, E. Rossi, V. Ludovini, V. Gregorc, L. Toschi, et al. Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients J. Clin. Oncol., August 1, 2005; 23(22): 5007 - 5018. [Abstract] [Full Text] [PDF]

				H. Shigematsu, T. Takahashi, M. Nomura, K. Majmudar, M. Suzuki, H. Lee, I. I. Wistuba, K. M. Fong, S. Toyooka, N. Shimizu, et al. Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas Cancer Res., March 1, 2005; 65(5): 1642 - 1646. [Abstract] [Full Text] [PDF]

				K. Altundag, O. Altundag, P. Morandi, and M. Gunduz Targeted Therapy for Targeted Patients: Trastuzumab in Adjuvant Treatment of Non-Small-Cell Lung Cancer J. Clin. Oncol., February 20, 2005; 23(6): 1325 - 1325. [Full Text] [PDF]

				C. J. Langer In Reply: J. Clin. Oncol., February 20, 2005; 23(6): 1326 - 1327. [Full Text] [PDF]

				G. Kalemkerian Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? J. Clin. Oncol., February 20, 2005; 23(6): 1325 - 1326. [Full Text] [PDF]

				E. Calvo, A. W. Tolcher, L. A. Hammond, A. Patnaik, J. S. de Bono, I. A. Eiseman, S. C. Olson, P. F. Lenehan, H. McCreery, P. LoRusso, et al. Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study Clin. Cancer Res., November 1, 2004; 10(21): 7112 - 7120. [Abstract] [Full Text] [PDF]

				R. Rosell Toward Customized Trastuzumab in HER-2/neu-Overexpressing Non-Small-Cell Lung Cancers J. Clin. Oncol., April 1, 2004; 22(7): 1171 - 1173. [Full Text] [PDF]